Seletalisib clinical trials
Also written UCB5857.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How each study uses seletalisib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- UCB5857
- 2
Studies by the year they started
3 studies that test it; most in 2013 (1)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses seletalisib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- UCB Proof of Concept Study in Patients With Primary Sjögren's SyndromeTerminatedPhase 2UCB CelltechNCT02610543Written as UCB5857
- Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy SubjectsCompletedPhase 1UCB CelltechNCT02207595Written as UCB5857
- Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic SubjectCompletedPhase 1UCB PharmaNCT02303509Written as UCB5857 Part 1
Codes
What other systems call seletalisib · ClinicalTrials.gg INT000702
- MeSH (NLM) C000620182seletalisibOne source NLM
- UNII (FDA) 64CW205BDDSELETALISIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27263741seletalisibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152320SeletalisibOne source FDA
- DrugBank DB12706One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000620182 | seletalisib | One source NLM |
| UNII (FDA) | 64CW205BDD | SELETALISIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27263741 | seletalisib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152320 | Seletalisib | One source FDA |
| DrugBank | DB12706 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.